GlassScriptPhysician profile
Lea D Aspinwall
NPI 1487271169
$1,463.90
in general payments reported to CMS, 2019-2025
19 companies · $68.98 in 2025
The $68.98 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $101 · 2024: $1,294 · 2025: $68.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,463.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $307.47 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $176.29 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.92 | 2023-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $137.27 | 2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $118.94 | 2024 | Voquezna |
| Genzyme Corporation | $100.63 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $86.01 | 2023-2024 | Dupixent |
| Janssen Biotech, INC. | $77.14 | 2024 | Stelara |
| Intercept Pharmaceuticals, INC. | $42.70 | 2024 | |
| Ironwood Pharmaceuticals, INC | $39.30 | 2023-2024 | Linzess |
| Pfizer INC. | $35.22 | 2024 | |
| Aimmune Therapeutics, INC. | $30.79 | 2024 | |
| Axonics, INC. | $25.73 | 2024 | Axonics |
| Ardelyx, INC. | $22.91 | 2024 | Ibsrela |
| Celgene Corporation | $21.84 | 2024 | Zeposia |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $21.80 | 2024 | Sucraid |
| Organon LLC | $18.80 | 2024 | |
| Lilly USA, LLC | $18.68 | 2024 | Omvoh |
| Mauna Kea Technologies, INC. | $15.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lea Aspinwall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.